Alliqua Biomedical Inc (ALQA) Expected to Post Earnings of -$0.02 Per Share

Share on StockTwits

Wall Street analysts expect that Alliqua Biomedical Inc (NASDAQ:ALQA) will post ($0.02) earnings per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Alliqua Biomedical’s earnings. Alliqua Biomedical reported earnings of ($0.79) per share in the same quarter last year, which suggests a positive year-over-year growth rate of 97.5%. The business is expected to report its next earnings report on Thursday, November 8th.

According to Zacks, analysts expect that Alliqua Biomedical will report full-year earnings of $5.14 per share for the current year. For the next fiscal year, analysts anticipate that the firm will report earnings of ($0.09) per share. Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research firms that cover Alliqua Biomedical.

Shares of ALQA stock opened at $2.45 on Tuesday. The firm has a market capitalization of $12.66 million, a price-to-earnings ratio of -0.38 and a beta of 1.12. Alliqua Biomedical has a one year low of $1.58 and a one year high of $4.50.

Alliqua Biomedical Company Profile

Alliqua BioMedical, Inc, a regenerative technologies company, commercializes regenerative medical products that assist the body in the repair or replacement of soft tissue. The company markets MIST Ultrasound Healing Therapy, a painless noncontact low-frequency ultrasound to promote healing; and Biovance Amniotic Membrane Allograft and Interfyl Human Connective Tissue Matrix, which are human biologic regenerative technologies.

See Also: What is a Tariff?

Get a free copy of the Zacks research report on Alliqua Biomedical (ALQA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Alliqua Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alliqua Biomedical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply